

CURRICULUM VITAE

Daniel Richard Wynn, MD, FACN, FAASM

Consultants in Neurology, Ltd.

1535 Lake Cook Road
Suite 601
Northbrook, Illinois 60062
Phone: 847/509-0270
Fax: 847/509-0273
Cellular : 847-744-1545
Email: dwynnmd@gmail.com

Academic Degrees/Graduate Education

	<u>Attended Institution & Location</u>	<u>Degree or Title</u>	<u>Field Study</u>
1988	Mayo Graduate School of Medicine Rochester, Minnesota	Fellow	Sleep Disorders/ Polysomnography
1987	Mayo Graduate School of Medicine Rochester, Minnesota	Fellow	EEG
1984-1987	Mayo Graduate School of Medicine Rochester, Minnesota	Resident/Fellow	Neurology
1983-1984	Mayo Graduate School of Medicine Rochester, Minnesota	Resident/Fellow	Internal Medicine
1979-1983	The Chicago Medical School North Chicago, Illinois	M.D.	Medicine
1973-1977	Reed College Portland, Oregon	B.A.	Biology

Certifications

American Board of Psychiatry and Neurology, Board Certified in Neurology, 10/88, #31061
American Board of Psychiatry and Neurology, Board Certified with Special Competence in Clinical
Neurophysiology, 3/92, certificate # 222; recertified May 2003
American Board of Clinical Neurophysiology, Fellow, Board Certified, Clinical Neurophysiology, FACN
American Board of Electrodiagnostic Medicine, Fellow, Board Certified, EMG and Neuromuscular Disease, 9/90,
#1434
American Board of Sleep Disorders, Medicine, Fellow, Board Certified Accredited Clinical Polysomnographer,
April 1989, FAASM
American College of Forensic Examiners, Board Certified, 8/97
National Board of Medical Examiners, Diplomate, Certificate #274967
Atomic Energy Commission, #OP-3519, Docket #55-4714 – Nuclear Reactor Operator, 1974

Licensure

Primary MD – 036-XXXXXX, Illinois
State Controlled Substance – 336-XXXXXX, Illinois
DEA licensure – active Class II-V
Atomic Energy Commission, #OP-3159, Docket #55-4714 – Nuclear Reactor Operator License
(inactive)

Hospital Affiliations

Highland Park Hospital, NorthShore University HealthSystem, Highland Park, Illinois
Evanston Hospital, NorthShore University HealthSystem, Evanston, Illinois
Glenbrook Hospital, NorthShore University HealthSystem, Glenview, Illinois
Skokie Hospital, NorthShore University HealthSystem, Skokie, Illinois
Advocate Illinois Masonic Medical Center, Chicago, Illinois

Professional Societies

Alpha Omega Alpha Honor Medical Society
American Academy of Clinical Neurophysiology
American Academy of Neurology
American Association of Neuromuscular and Electrodiagnostic Medicine
American College of Forensic Examiners
American Electroencephalographic Society
American Epilepsy Society
American Medical Association
American Pain Society
Chicago Medical Society
Illinois State Medical Society
Midwest Pain Society
National Multiple Sclerosis Society

Honors, Awards and Research

- Present Director, Clinical Research, Consultants in Neurology, Ltd.
Director, Consultants in Neurology Multiple Sclerosis Center
Member, Clinical Advisory Committee, National Multiple Sclerosis Society,
Chicago-Greater Illinois Chapter
Board Member, National Multiple Sclerosis Society
Member, Illinois Medical Advisory Board, Illinois Secretary of State, State of Illinois
Director, Consultants in Neurology Sleep Disorders Laboratories
Ad Hoc Reviewer: Headache, Journal Neuroscience, NeuroRehabilitation and Neural
Repair
- 2006 Volunteer of the Year, National Multiple Sclerosis Society, Greater Illinois Chapter.
- 1993-2006 Medical Director, The Chicago Wolves Professional Hockey Team
- 2000 Valedictorian, Multiple Sclerosis Leadership Award, Deloitte and Touché LLP and
National Multiple Sclerosis Society, Greater Illinois Chapter, September 14, 2000
Member, Electronic Media Committee, American Academy of Neurology
Member, Electronic Media Committee, American Association of Electrodiagnostic
Medicine
Neurology Consultant, Ann Kiley Developmental Center, Waukegan, Illinois
- 1990-1995 Committee Member, Physical Medicine and Rehabilitation Committee, Highland Park
Hospital
- 1988-1994 Medical Director, Lake Forest Hospital Sleep Disorders Center, Lake Forest, Illinois
- 1988-1990 Medical Director, Headache Treatment Center, Pain Treatment Center, Lake Forest
Hospital, Lake Forest, Illinois
- 1983-1988 Immunology and Neuroepidemiology Research in Multiple Sclerosis, Departments of
Neurology, Epidemiology and Laboratory Medicine. Mayo Clinic, Mayo Graduate
School of Medicine, Rochester, Minnesota
- 1983 Class Salutatorian; class rank 2/135, graduating class of 1983. The Chicago Medical
School, North Chicago, Illinois
- 1982 Alpha Omega Alpha Honor Medical Society
Awarded Junior Year. The Chicago Medical School, North Chicago, Illinois
- 1980 Melvyn Leichtling Annual Oncology Research Award
Scholarship for Immunology/Oncology Research, The University of the Health
Sciences, The Chicago Medical School, Department of Obstetrics
and Gynecology, Cook County Hospital, Chicago, Illinois
- 1974 Nuclear Reactor Operator, TRIGA Research Nuclear Reactor, Reed College,
Portland, Oregon
- 1971 National Science Foundation Scholar, Toxicology,
National Science Foundation Student Science Training Program, Luther College,
Decorah, Iowa

Selected Publications and Presentations

1. LaGanke C, Wynn D, McCague K, Barbato LM, Hashmonay R, No Effect On Incidence Of Infection After Therapy Switch To Fingolimod, submitted this for The 27th Annual Meeting of the CMSC and the 5th Cooperative Meeting of the CMSC-ACRIMS (CMSC) Meeting, Orland, Florida, May 2013 (in press).
2. Schapiro R, Wynn D, Lissin D, AL-Sabbagh A, Jones E, Pike J, The burden of multiple sclerosis-related spasticity on indirect costs and requirement for non-professional care: results of a cross-sectional study in the USA. Presented at the 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 2013, (in press).
3. Schapiro R, Wynn D, Lissin D, AL-Sabbagh A, Jones E, Pike J, Impact of spasticity on healthcare resource utilisation: results of a cross-sectional study in the USA. Presented at the 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 2013, (in press).
4. Polman C, Bowen JD, Barkhof F, Bates D, Wynn D, Sanders E, Wolf C, Morris DL, Vandendriessche A, Duda P, Weinkauff B, Lynn F, Bennett B, CDP32322 manuscript (NCT00484536): Randomized, Double-blind, Placebo-Controlled Phase 2 Trial of CDP323 in Multiple Sclerosis. PLOS ONE. *In press*
5. Wynn D, Cascione M, Agashivala N, McCague K, Pestrich L, Schofield L, Barbato L, Kim E, Reasons for switching first-line disease modifying therapies in multiple sclerosis. Baseline data from the trial to Evaluate Patient Outcomes, safety and tolerability of fingolimod (EPOC). Presented at the 28th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012. Multiple Sclerosis Journal 2012; 18: (S4) 55-277.
6. Cascione M, Wynn D, Agashivala N, McCague K, Pestrich L, Schofield L, Kim E, Barbato L. Summary scores for patient-reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient Outcomes, safety and tolerability of fingolimod (EPOC). Presented at the 28th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012. Multiple Sclerosis Journal 2012; 18: (S4) 55-277.
7. Wynn D, Shapiro R, Lissin D, AL-Sabbagh A, Jones E, Pike J, Onset of multiple sclerosis-related spasticity and its impact on health-related quality of life as measured by EQ-5D and HAQUAMS, Presented at the 28th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012. Multiple Sclerosis Journal 2012; 18: (S4) 55-277.
8. Schapiro R, Wynn D, Lissin D, AL-Sabbagh A, Jones E, Pike J, The burden of multiple sclerosis-related spasticity on indirect costs and requirement for non-professional care: results of a cross-sectional study in the USA, Presented at the 28th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012. Multiple Sclerosis Journal 2012; 18: (S4) 55-277.
9. Schapiro R, Wynn D, Lissin D, AL-Sabbagh A, Jones E, Pike J, Impact of Spasticity on Healthcare Resource Utilization: Results of a Cross-Sectional Study in the USA, Presented at the 28th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012. Multiple Sclerosis Journal 2012; 18: (S4) 55-277
10. Wynn D, McMillan S, Corsino A, Hepner A, Pseudobulbar Affect In MS; Evaluation of Baseline Patterns in a Double-Blind, Placebo-Controlled Study. Presented at The 6th World Congress on Controversies in Neurology, Vienna, Austria, March 11, 2012

Selected Publications and Presentations

11. Wynn D, McMillan S, Corsino A, Hepner A, Pseudobulbar Affect in MS: Baseline Interrelations in a Study Cohort. Presented at the Forth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis Meeting, San Diego, California, 2012
12. Motl RW, McAuley E, Wynn D, Sandroff B, Suh Y. Physical activity, self-efficacy, and health-related quality of life in persons with multiple sclerosis: analysis of associations between individual-level changes over one year. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation* 2012.
13. Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. *Mult Scler* 2012;18:843-852.
14. Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. *Mult Scler* 2011;17:181-191.
15. Motl RW, McAuley E, Wynn D, Vollmer T. Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study. *Am J Phys Med Rehabil* 2011;90:372
16. Motl RW, McAuley E, Wynn D, Suh Y, Weikert M. Effects of change in fatigue and depression on physical activity over time in relapsing-remitting multiple sclerosis. *Psychol Health Med* 2011;16:1-11.
17. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. *Ann Neurol* 2011;69:75-82.
18. Coles AJ, Fox E, Vladic A, Wynn D, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. *Lancet Neurol* 2011;10:338-348.
19. Wynn DR, Emerging Treatments for Pseudobulbar Affect, presented at the 4th World Congress on Controversies in Neurology (CONy), Barcelona, Spain, October, 2010
20. Kaye R, Hepner A, Wynn DR, Dextromethorphan/Quinidine for Pseudobulbar Affect: Efficacy Evaluation in Patients Using Concomitant SSRIs, presented at the 4th World Congress on Controversies in Neurology (CONy), Barcelona, Spain, October, 2010
21. Wynn, D on behalf of the CAMMS223 Study Group, Disability-Free Efficacy. Presented at the 26th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS)/15th Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS), Gothenburg, Sweden, October, 2010
22. Herbert, J, Wynn, D on behalf of the CAMMS223 Study Group. Alemtuzumab's efficacy in the CAMMS223 Trial as assessed with the multiple sclerosis severity score. Presented at the 26th European Committee on the Treatment and Research in Multiple Sclerosis (ECTRIMS)/15th Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS), Gothenburg, Sweden, October, 2010

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.